Proven HIV Prevention Strategies by unknown
What is EvidEncE of EffEctivEnEss?
Since the AIDS epidemic first appeared nearly three decades ago, scientific research and detailed observation 
of epidemiological trends have identified a range of effective strategies for preventing all routes of HIV 
transmission—sexual, blood borne, and mother-to-child.
However, most people at high risk of HIV exposure currently lack meaningful access to effective prevention.1 
According to an analysis by UNAIDS and the World Health Organization, expanded access to proven 
prevention strategies could avert half of the 62 million new HIV infections projected to occur between 2005  
and 2015.2 Another analysis found that in Sub-Saharan Africa alone, expanded prevention could prevent 55%  
of the 53 million new infections projected to occur in the region between 2003 and 2020.3
Preventing new HIV infections is an urgent global priority. Already, HIV has resulted in history’s single 
sharpest reversal in international development.4 In Asia—where infection levels are a mere fraction of those 
reported in Africa—experts project that the epidemic will push an additional 6 million people into poverty by 
2015 unless greater success is achieved in curbing the spread of HIV.5 Globally, an estimated 7,000 new HIV 
infections occur each day, and the number of new HIV infections in 2007 was more than 2.5 times greater 
than the increase in the number of people receiving antiretroviral medications.6
There is no single solution—no “magic bullet”—to prevent HIV. However, experience in diverse settings—in 
all regions and in different national income strata—indicate that sharp reductions in HIV infection rates are 
feasible if evidence-based prevention measures are implemented. The most effective prevention programs 
are those that use a combination of strategies to achieve maximum impact.7 Following are descriptions of the 
major strategies that, when used in combination, are effective in preventing sexual, blood borne, and mother-
to-child transmission.
ProvEn hiv  
PrEvEntion stratEgiEs
fact shEEt  
thE global hiv PrEvEntion Working grouP
Assessing the effectiveness of 
HIV prevention programs is  
inherently difficult. Determining 
what causes an event never to  
occur is intrinsically more  
complicated than discerning  
the cause of something that  
can be readily observed. 
For drugs, vaccines and medical 
devices, the randomized controlled 
trial (RCT) is universally regarded 
as the gold standard for evaluating 
efficacy of a new product. RCTs 
have similarly demonstrated the 
efficacy of a wide range of  
HIV-prevention interventions,  
although demonstrating that an 
intervention has efficacy under 
the controlled conditions of a 
clinical trial does not automati-
cally indicate that the approach 
will be effective in the real world. 
Ideally, RCTs for experimental 
HIV-prevention strategies should 
be complemented by effectiveness 
studies in the field, particularly 
studies that gauge the impact of 
multiple prevention strategies 
used in combination.
Observational data on national  
responses and epidemiological 
and behavioral impact often  
provide the best information 
on prevention effectiveness.8 
Although observational data are 
often difficult to interpret and 
cannot tie behavioral or epide-
miological trends to particular 
actions, such evidence can help 
clarify the array of factors that 
contribute to population-wide 
shifts in behaviors.
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PrEvEnting sExual 
transmission – What Works
Globally, sexual transmission is responsible for the 
majority of new HIV infections.
behavior change Programs
Numerous randomized controlled trials—in both 
high-income9 and developing countries10 and extensive 
observational research11 have demonstrated that 
behavioral interventions can be highly effective 
in reducing sexual risk behaviors and associated 
HIV infections. To date, most studies of behavioral 
interventions have been carefully controlled efficacy 
trials in well-defined populations; less information is 
available regarding population-level effectiveness of 
these strategies, although observational and historical 
studies in diverse settings have documented a positive 
public health impact from various behavioral strategies. 
Studies have documented the efficacy of behavior 
change programs among a broad range of populations 
at risk of HIV infection, including: 
• Sex workers12 
• Men who have sex with men13 
• Substance users14 
• Heterosexual adults15 
• Women16 
• Young people17 
Most efficacy studies have followed participants  
for limited periods—typically for no more than  
12-18 months .
Evidence-based behavior change programs typically 
have one or more aims—encouraging young people 
to remain sexually abstinent or delay initiating sexual 
activity, decreasing the number of sex partners, or 
using condoms consistently and correctly if sexually 
active. Studies in high-income countries indicate that 
comprehensive risk reduction programming is more 
effective in promoting safer sexual behaviors among 
young people than interventions that exclusively 
promote abstinence.18 
Behavior change programs may focus on individuals, 
groups or entire communities. Strategies that affect 
social dynamics are especially important for individuals 
who engage in relatively low levels of risk behavior but 
nevertheless confront considerable risk of becoming 
infected.19 Increasingly, public health experts advise that 
individually-focused behavioral interventions ought to 
be complemented by structural interventions that aim 
to reduce risk by altering the social, legal or physical 
environments in which risk behavior may occur.20 
condoms 
Condoms are highly effective at preventing sexual 
transmission of HIV. An analysis by the U.S. National 
Institutes of Health of available studies concluded that 
consistent use of condoms can reduce an individual’s 
risk of HIV transmission by 85%.21 Population-level 
data on the impact of condom promotion programs are 
more limited. 
While most research has focused on the efficacy of male 
condoms, evidence also exists that female condoms are 
effective in the prevention of sexual HIV transmission as 
reflected by the 2009 approval by the US Food and Drug 
Administration of FC2, a low cost female condom.
hiv testing
Timely diagnosis of HIV infection promotes HIV 
prevention. According to studies in the U.S., people with 
undiagnosed HIV infection are 3.5 times more likely to 
transmit HIV than individuals who have tested HIV-
positive.22 Data do not clearly indicate that a negative test 
result is associated with sexual risk reduction. Currently, 
it is estimated that 80% of people living with HIV in low- 
and middle-income countries remain undiagnosed23; 
non-governmental informants report that HIV 
counseling and testing services were not widely available 
in 70% of countries reporting data to UNAIDS.24
Prompt diagnosis and treatment of other stis
Sexually transmitted infections (STIs) such as syphilis, 
gonorrhea and herpes simplex virus type 2 increase 
the risk of HIV acquisition and transmission by two to 
five times.25 Prompt diagnosis and treatment of STIs 
plays a critical role in efforts to prevent sexual HIV 
transmission,26 although studies aiming to document 
population-level benefits from STI treatment strategies 
have reached conflicting results. In particular, questions 
remain regarding the optimal timing and means of 
harvesting the potential of STI treatment to strengthen 
HIV-prevention efforts. Available data suggest that 
STI control efforts are most effective at lowering HIV 
incidence when they are initiated as early as possible in 
the course of a country’s epidemic and when they are 
focused on people at highest risk.27 
medical male circumcision
Clinical trials in Kenya, South Africa and Uganda indicate 
that medical male circumcision lowers by approximately 
60% the risk of female-to-male sexual HIV transmission.28 
However, risk of transmission may actually increase if a 
newly-circumcised male engages in sexual intercourse 
before his circumcision wounds have healed. Whether 
medical male circumcision confers a prevention benefit 
for women during heterosexual intercourse remained 
unclear and was still being studied in early 2009.
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PrEvEnting blood-bornE 
transmission – What Works
Subcutaneous exposure is the most efficient route of 
HIV transmission.32 Injection drug use is a primary 
driver of the epidemic in many parts of Asia and 
accounted for more than 60% of new reported HIV 
diagnoses in Eastern Europe and Central Asia in 2006.33 
Receiving one or more units of HIV-infected blood 
results in HIV infection nearly 90% of the time.34 
harm reduction Programs for injection drug users
Harm reduction for injection drug users involves a 
package of essential services, including access to clean 
syringes and injection equipment, substitution drug 
treatment therapy, counseling, essential HIV and other 
health services, and evidence-based programs to reduce 
demand for drugs.35 Extensive evidence demonstrates 
that harm reduction programs reduce the risk of HIV 
transmission without contributing to an increase in 
drug use.36, 37 According to the U.S. National Institute 
on Drug Abuse, harm reduction programs “serve as a 
bridge...by offering opportunities for HIV testing, and 
by providing referrals for drug abuse treatment.”38
Observational studies underscore the potential HIV 
prevention impact of harm reduction services. An 
international analysis of 81 cities found that the number 
of people infected with HIV decreased an average of 6% 
in cities with needle and syringe programs, while HIV 
rates increased 6% in cities without these programs.39 
blood supply safety 
In developed countries, routine screening of the blood 
supply, combined with efforts to reduce unnecessary 
transfusions and to preclude high-risk donors, has 
virtually eliminated the risk of HIV transmission 
through donated blood.40 In the U.S., blood donations 
have been screened for HIV antibodies since 1985 and 
for the p24 antigen since 1996.41 
The safety of blood supplies in low- and middle-income 
countries has improved in recent years. Through 
the President’s Emergency Plan for AIDS Relief, for 
example, the U.S. government provided more than $74 
million in assistance to 14 countries over a 14-month 
period in 2004-2005 to improve national blood control 
systems, with an additional $51 million in funding in 
the pipeline.42 Nevertheless, at least 34 countries report 
that they fail to screen all donated blood for HIV in 
accordance with minimum quality standards, and the 
World Health Organization reports that more than 1 
million units of blood were still not properly screened 
in 2008.43
infection control in health care settings
Countries that require health workers to adopt 
“universal precautions” have succeeded in making 
occupational HIV transmission extremely rare in 
health care settings.44 This approach treats every 
patient as potentially infectious, requires workers 
to wear protective gear, and trains workers to use 
syringes properly and sterilize all equipment and 
surfaces. Under standard protocols for universal 
precautions, equipment used to administer injections 
are automatically disposed of safely. The feasibility of 
universal precautions depends on workers’ ready access 
to standard protective gear and safe technologies.
In 2000, unsafe injection practices were estimated to be 
responsible for 5% of new HIV infections.45 Avoiding 
reuse of injection equipment and proper disposal of 
such devices are critical elements of comprehensive 
HIV prevention. 
antirEtroviral-basEd hiv PrEvEntion stratEgiEs
Emerging evidence suggests 
that antiretroviral agents may 
play a potentially potent role in 
preventing new HIV infections 
through sexual transmission. 
Such strategies have yet to 
be validated by clinical trials, 
although a number of studies 
are under way to test a range of 
antiretroviral-based prevention 
approaches. The feasibility of 
preventing HIV transmission 
through timely administration 
of antiretrovirals is premised on 
voluminous evidence linking the 
risk of transmission to viral load 
in plasma.29 As antiretrovirals 
dramatically reduce viral load 
when properly administered, it is 
assumed they may also lower the 
risk of HIV transmission. 
Antiretrovirals may help slow the 
spread of HIV in several ways. 
Mathematical modeling suggests 
that universal knowledge of 
HIV serostatus and access to 
early HIV therapy could virtually 
eradicate HIV transmission.30 
As described below, timely 
administration of antiretrovirals 
significant lowers the risk that an 
HIV-infected mother will pass the 
virus to her newborn. In addition, 
studies are ongoing to evaluate 
the efficacy of pre-exposure 
antiretroviral prophylaxis. 
Post-exposure antiretroviral 
prophylaxis has long been 
standard practice following a 
potential HIV exposure in health 
care settings, and available 
evidence has led public health 
authorities to endorse the 
approach following sexual and 
injection-drug exposure, as well.31 
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PrEvEnting mothEr-to-child 
transmission – What Works 
An estimated 370,000 children under age 15 became 
infected with HIV in 2007, with the vast majority 
contracting HIV during gestation or birth or as a result 
of breast-feeding. Nine out of 10 newborns who become 
infected with HIV live in Sub-Saharan Africa.46 In the 
absence of prophylactic intervention or when breast-
fed, children born to an HIV-infected mother stand 
a 15–30% chance of becoming infected; in the case of 
prolonged breast-feeding, the risk of transmission is as 
great as 45%.47 
Implementation of a comprehensive package of 
prevention services has reduced the risk of transmission 
to below 1% in high-income countries.48 Where such 
services have been brought to scale in resource-limited 
settings, comparable success has been achieved.49
antiretroviral drugs
A landmark clinical trial in 1999 and subsequent 
studies have shown that timely administration of short, 
inexpensive doses of antiretrovirals to HIV-infected 
mothers and their newborns sharply reduces the risk of 
HIV transmission by nearly 50%.50 Research advances 
suggest that even better antiretroviral regimens 
will soon be available to further reduce the risk of 
transmission, although results from these studies are 
unlikely to be available before mid- to late 2009.51 
breast-feeding alternatives
The chance that an HIV-infected mother will transmit 
HIV to her newborns increases by at least 50% with 
prolonged breast-feeding. Ideally, HIV-infected mothers 
should have access to breast-feeding alternatives, such as 
infant formula, although the lack of access to safe water 
supplies impedes efforts to provide meaningful infant 
feeding alternatives in many resource-limited settings. 
Early weaning from breast-feeding may also help reduce 
HIV transmission52, although evidence suggests that early 
weaning does not increase HIV-free survival of infants.53 
caesarean delivery
Caesarean delivery also significantly reduces the risk 
of mother-to-child HIV transmission.54 However, 
caesarean deliveries are often not available or practical 
in developing countries, where many women lack 
access to hospital birthing facilities.
structural intErvEntions to rEducE vulnErability to hiv
While numerous studies have 
demonstrated the effectiveness 
of specific technical interventions 
to prevent new infections, HIV 
prevention is more than merely 
technical. To maximize the 
effectiveness of combination HIV 
prevention, prevention technologies 
should be complemented with 
approaches designed to address  
the social determinants of HIV  
risk and vulnerability.
Policy changes—such as Thailand’s 
100% condom program, which 
mandated condom use in brothels, 
or more recent laws in numerous 
settings that permit pharmacies 
to sell sterile syringes—have long 
played a role in public health efforts 
to prevent new HIV infections.55 In 
part due to the historic under-
prioritization of social science 
research for HIV prevention, 
fewer rigorous studies have 
been undertaken on structural 
interventions than on experimental 
technical prevention approaches.
As the epidemic’s burden on 
women and girls has steadily 
increased over the last 10–15 
years, it has become plain that 
gender inequity and women’s 
disempowerment are increasing the 
vulnerability of women and girls to 
HIV infection. In a recent study in 
rural South Africa, each additional 
year of education was found to be 
associated with a 7% reduction 
in the risk of HIV infection56, 
suggesting that initiatives to 
promote universal education 
beyond primary schooling may 
constitute a potent HIV-prevention 
strategy. As women’s risk of HIV 
infection is closely correlated 
with experience of gender-based 
violence57, initiatives that prevent 
violence against women and alter 
the sexual norms of men and 
boys also play a role in reducing 
women’s vulnerability. According 
to information provided in 2009 
by the International Center for 
Research on Women, 13 of 33 Sub-
Saharan African countries for which 
information was available have laws 
in place restricting the ability of 
women to own or inherit property; 
revising laws to recognize and enforce 
women’s property rights represents 
a potentially potent structural 
intervention to empower women and 
thereby reduce their ability to abstain 
from sex or to insist that their male 
partners use a condom.
Legal and policy structures also 
perpetuate and reinforce the 
vulnerability of populations most at 
risk. More than 80 countries (nearly 
all of them developing countries) 
impose criminal penalties for 
consensual sexual relations 
between the same sex, including 
seven countries that provide for 
the death penalty.58 Offering or 
soliciting sex is illegal in more than 
110 countries, and more than 50 
countries provide for coercive or 
compulsory treatment or the death 
penalty for individuals convicted of 
using drugs.59 Repeal of these and 
other discriminatory laws is needed 
to support evidence-based HIV 
prevention efforts.
Building the evidence base for 
structural interventions or social 
change strategies to prevent 
HIV infections will require 
researchers to pursue a broad 
range of research strategies. While 
randomized controlled trials may 
be suitable for certain well-defined 
structural interventions, they will be 
inappropriate for certain strategies 
or in certain contexts.60 Significantly 
greater financial and institutional 
support is merited for social 
science research strategies that aid 
in expanding the evidence base for 
HIV prevention. 
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